OSR (OSRH)
Combines cancer immunotherapies and regenerative biologics with Korean neurovascular-device distribution.
Something off on this page? Send us feedback.
Operates a health-care holding portfolio spanning oral cancer immunotherapies, regenerative biologics, and Korean neurovascular-device distribution and logistics. Its hub-and-spoke structure combines development-stage biotechnology with commercial device activity across the United States, South Korea, and Switzerland.
Combines three operating platforms: Vaximm’s oral cancer-immunotherapy programs, Darnatein’s design-augmented biologics for bone, cartilage, and degenerative conditions, and RMC’s Korean neurovascular-device distribution and logistics operation. A diabetes-focused medical-device developer broadens the stated portfolio.
Pairs potential R&D, licensing, milestone, and royalty economics for the biotechnology assets with RMC’s product distribution and planned logistics-service revenue. Operations span the United States, South Korea, and Switzerland, with Paju serving as a corporate hub and Basel as a drug-development hub.
Centralizes resources at the holding-company hub while wholly owned subsidiaries pursue separate scientific and commercial specialties. The biotechnology portfolio has no approved commercial drugs and depends on development, trials, regulatory review, intellectual-property protection, and commercialization or licensing arrangements. RMC depends on distribution volume and logistics-contract wins. The holding-company structure coordinates the portfolio across multiple legal entities and jurisdictions.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.5M · Total debt $578.2K · Total assets $166.6M · Shareholders' equity $104.3M
- Revenue
- $315.7K
- Operating income
- −$3.0M
- Net income
- −$1.0M
No dividends on record.
| Institutions11 holders · as of Mar 31, 2026 | 0.83% | 292.9K shares | |
| Insiders2 holders · as of Apr 16, 2026 | 36.23% | 12.72M shares | |
| Strategic holders4 holders · as of Apr 22, 2026 | 43.57% | 15.30M shares | |
| Otherremainder | 19.37% | 6.80M shares |
35.12M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Kuk Hyoun HwangInsiderdirector, 10 percent owner, officer: President and CEO | 36.16% | 12.70M | Form 4filed Feb 19, 2025 ↗ |
BCM Europe AGStrategic10 percent owner | 21.45% | 7.53M | Form 4filed Feb 19, 2025 ↗ |
Bellevue Capital Management LLCStrategic10 percent owner | 8.90% | 3.12M | Form 4filed Feb 19, 2025 ↗ |
joint protein central inc.Strategic | 7.41% | 2.60M | 13Gfiled Apr 22, 2026 ↗ |
Bellevue Global Life Science Investors LLCStrategic10 percent owner | 5.82% | 2.04M | Form 4filed Feb 19, 2025 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Medtronic
Broad pressure in spinal fusion and neurovascular hospital channels.
- Stryker
Neurovascular systems and spine implants meet the same hospital demand.
- Abbott
FreeStyle Libre sets the diabetes-monitoring benchmark.
- Dexcom
Dexcom G7 competes for glucose-monitoring adoption and channels.
- Candel Therapeutics
CAN-3110 targets the same high-grade-glioma trial ecosystem.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OSR | $0.1165 | 0.00% | $3.9M | — | — | 2.1 | −72.2% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Stryker | $314.00 | +0.58% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| Abbott | $111.49 | +0.93% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Dexcom | $89.59 | −0.11% | $33.85B | 35.5 | 32.0 | 6.8 | +13.1% |
| Candel Therapeutics | $13.17 | +2.49% | $967.2M | — | — | — | — |
| Median | 33.9 | 19.2 | 4.4 | +13.1% |